Avacta Presents Updated Clinical Data Showing Encouraging Early Efficacy Signals For AVA6000 In Salivary Gland Cancers At ASCO 2026

(MENAFN - GlobeNewsWire - Nasdaq) Multiple confirmed partial and minor responses observed in patients with SGC Continuing very good safety profile, with removal of the lifetime maximum doxorubicin ...